Seebri is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 15 US drug patents filed from 2015 to 2018. Out of these, 2 drug patents are active and 13 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 20, 2028. Details of Seebri's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6521260 | Carrier particles for use in dry powder inhalers |
Jan, 2016
(8 years ago) |
Expired
|
| US6582678 | Carrier particles for use in dry powder inhalers |
Apr, 2018
(6 years ago) |
Expired
|
| US6528678 | Phosgene-free process for preparing carbamates |
Apr, 2018
(6 years ago) |
Expired
|
| US7229607 | Treatment of respiratory disease |
Apr, 2021
(3 years ago) |
Expired
|
| US8029768 | Treatment of respiratory diseases |
Apr, 2021
(3 years ago) |
Expired
|
| US7736670 | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) |
Expired
|
| US9931304 | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) |
Expired
|
| US8580306 | Particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) |
Expired
|
| US8303991 | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) |
Expired
|
| US8048451 | Pharmaceutical compositions for inhalation |
Jun, 2021
(3 years ago) |
Expired
|
| US8435567 | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun, 2021
(3 years ago) |
Expired
|
| US8956661 | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun, 2021
(3 years ago) |
Expired
|
| US9962338 | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) |
Expired
|
| US8479730 | Inhaler device |
Oct, 2028
(4 years from now) | Active |
| US8182838 | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Seebri's patents.
Latest Legal Activities on Seebri's Patents
Given below is the list of recent legal activities going on the following patents of Seebri.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed | 24 Jun, 2024 | US8303991 (Litigated) |
| Expire Patent | 04 Dec, 2023 | US8048451 |
| Maintenance Fee Reminder Mailed | 19 Jun, 2023 | US8048451 |
| Expire Patent | 27 Mar, 2023 | US8956661 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Mar, 2023 | US8029768 |
| Maintenance Fee Reminder Mailed | 10 Oct, 2022 | US8956661 |
| Expire Patent | 18 Jul, 2022 | US7736670 |
| Expire Patent | 13 Jun, 2022 | US9962338 |
| Expire Patent | 10 May, 2022 | US9931304 |
| Maintenance Fee Reminder Mailed | 31 Jan, 2022 | US7736670 |
FDA has granted several exclusivities to Seebri. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Seebri, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Seebri.
Exclusivity Information
Seebri holds 1 exclusivities. All of its exclusivities have expired in 2018. Details of Seebri's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 29, 2018 |
Several oppositions have been filed on Seebri's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Seebri's generic, the next section provides detailed information on ongoing and past EP oppositions related to Seebri patents.
Seebri's oppositions filed in EPO
Seebri has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 30, 2012, by Teva Uk Limited. This opposition was filed on patent number EP04768542A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP04727320A | Dec, 2018 | Teva UK Limited | Revoked |
| EP10181354A | Dec, 2018 | Teva UK Limited | Patent maintained as amended |
| EP04768542A | Aug, 2012 | Teva UK Limited | Revoked |
US patents provide insights into the exclusivity only within the United States, but Seebri is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Seebri's family patents as well as insights into ongoing legal events on those patents.
Seebri's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Seebri's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 20, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Seebri Generics:
Glycopyrrolate is the generic name for the brand Seebri. 42 different companies have already filed for the generic of Seebri, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Seebri's generic
About Seebri
Seebri is a drug owned by Novartis Pharmaceuticals Corp. It is used for managing long-term airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD). Seebri uses Glycopyrrolate as an active ingredient. Seebri was launched by Novartis in 2015.
Market Authorisation Date:
Seebri was approved by FDA for market use on 29 October, 2015.
Active Ingredient:
Seebri uses Glycopyrrolate as the active ingredient. Check out other Drugs and Companies using Glycopyrrolate ingredient
Treatment:
Seebri is used for managing long-term airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD).
Dosage:
Seebri is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15.6MCG/INH | POWDER | Discontinued | INHALATION |